PuraPharm Corp Ltd
HKEX:1498
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PuraPharm Corp Ltd
Operating Income
PuraPharm Corp Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PuraPharm Corp Ltd
HKEX:1498
|
Operating Income
-HK$7.9m
|
CAGR 3-Years
61%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Operating Income
-$3.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Operating Income
HK$1.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
18%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Operating Income
¥6.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Operating Income
HK$13.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Operating Income
-$39.2m
|
CAGR 3-Years
54%
|
CAGR 5-Years
28%
|
CAGR 10-Years
-15%
|
|
PuraPharm Corp Ltd
Glance View
PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. The firm operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.
See Also
What is PuraPharm Corp Ltd's Operating Income?
Operating Income
-7.9m
HKD
Based on the financial report for Dec 31, 2025, PuraPharm Corp Ltd's Operating Income amounts to -7.9m HKD.
What is PuraPharm Corp Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
30%
Over the last year, the Operating Income growth was 58%. The average annual Operating Income growth rates for PuraPharm Corp Ltd have been 61% over the past three years , 30% over the past five years .
